Transarterial Chemoembolization Combined With Radiofrequency Ablation Versus Hepatectomy for Hepatocellular Carcinoma: A Meta-Analysis

Dan, Yuan; Meng, Wenjun; Li, Wenke; Chen, Zhiliang; Lyu, Yongshuang; Yu, Tianwu

doi:10.3389/fsurg.2022.948355

Cited by 4 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The DCR in the experimental group was 93.33%, while that in the control group was 82.22%, with a statistically significant difference between the two groups ( P < 0.05). This indicated that the short-term clinical efficacy of combination therapy was superior to that of monotherapy[ 26 , 27 ]. These results suggest that TACE + RFA may enhance the body’s absorption and sensitivity to chemotherapeutic drugs.…”

Section: Discussionmentioning

confidence: 99%

Radiofrequency ablation combined with transcatheter arterial chemoembolization for recurrent liver cancer

Guo,

Zhao,

Cai

et al. 2024

World J Gastrointest Surg

View full text Add to dashboard Cite

BACKGROUND The recurrence rate of liver cancer after surgery is high. Radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) is an effective treatment for liver cancer; however, its efficacy in recurrent liver cancer remains unclear. AIM To investigate the clinical effect of TACE combined with RFA in the treatment of recurrent liver cancer. METHODS Ninety patients with recurrent liver cancer were divided into 2 groups according to treatment plan: Control (RFA alone); and experimental [TACE combined with RFA (TACE + RFA)]. The incidence of increased alanine aminotransferase levels, complications, and other indices were compared between the two groups before and after the procedures. RESULTS One month after the procedures, the short-term efficacy rate and Karnofsky Performance Status scores of the experimental group were significantly higher than those of the control group (P < 0.05). Alpha-fetoprotein (AFP) and total bilirubin levels were lower than those in the control group (P < 0.05); The overall response rate was 82.22% and 66.67% in the experimental and control groups, respectively; The disease control rate was 93.33% and 82.22% in the experimental and control groups, respectively, the differences are statistically significant (P < 0.05). And there were no statistical differences in complications between the two groups (P > 0.05). CONCLUSION TACE + RFA was effective for the treatment of recurrent liver cancer and significantly reduced AFP levels and improved various indices of liver function.

show abstract

Section: Discussionmentioning

confidence: 99%

Radiofrequency ablation combined with transcatheter arterial chemoembolization for recurrent liver cancer

Guo,

Zhao,

Cai

et al. 2024

World J Gastrointest Surg

View full text Add to dashboard Cite

show abstract

“…38 However, when comparing TACE-ablation to SR as firstline therapy in this patient population, a meta-analysis conducted by Dan et al evaluated OS, DFS, and major complications in HCC patients who were treated with SR or TACE-ablation. 39 SR was found to have superior long-term survival outcomes in regard to 5-year OS, 3-year DFS, and 5-year DFS. 39 While the study initially found no significant differences in 1-year OS, 3-year OS, and 1-year DFS, significant heterogeneity was found between many of the groups and an additional meta-analysis was subsequently conducted with propensity score-matched cohorts.…”

Section: Comparison Of Tace-ablation To Other Modalitiesmentioning

confidence: 92%

“…39 SR was found to have superior long-term survival outcomes in regard to 5-year OS, 3-year DFS, and 5-year DFS. 39 While the study initially found no significant differences in 1-year OS, 3-year OS, and 1-year DFS, significant heterogeneity was found between many of the groups and an additional meta-analysis was subsequently conducted with propensity score-matched cohorts. This revealed superior 3-year OS and 5-year OS in the SR group when compared with TACE–ablation.…”

Section: Comparison Of Tace–ablation To Other Modalitiesmentioning

confidence: 92%

See 1 more Smart Citation

Chemoembolization Plus Ablation: Current Status

Dadrass,

Acree,

Kim

2023

Semin intervent Radiol

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. The treatment landscape for HCC has evolved significantly over the past decade, with several modalities available to treat various stages of disease. The Barcelona Clinic Liver Cancer (BCLC) system provides a foundation for treatment guidance. However, given the complex nature of HCC, a more nuanced approach is often required, especially for lesions sized between 3 and 5 cm. This review aims to analyze the available treatments for early-stage HCC lesions between 3 and 5 cm, with a focus on the therapeutic potential and efficacy of transarterial chemoembolization (TACE)–ablation. Additional therapies including TACE, ablation, transarterial radioembolization, and surgical resection are also reviewed and compared with TACE–ablation. TACE–ablation is a viable therapeutic option for early-stage HCC lesions between 3 and 5 cm. Surgical resection remains the gold standard. Although recent studies suggest radiation segmentectomy may be a curative approach for this patient population, further studies are needed to compare the relative efficacies between TACE–ablation and radiation segmentectomy.

show abstract

Microwave ablation followed by cTACE in 5-cm HCC lesions: does a single-session approach affect liver function?

Floridi,

Cacioppa,

Rossini

et al. 2024

Radiol med

View full text Add to dashboard Cite

Purpose Microwave ablation (MWA) and conventional transarterial chemoembolization (cTACE) are locoregional treatments commonly performed in very early, early and intermediate stages of hepatocellular carcinoma (HCC). Despite combined locoregional approaches have shown encouraging results in obtaining complete tumor necrosis, their application in a single session is poorly described. Our aim was to evaluate the safety and efficacy of single-session MWA and cTACE treatment in 5-cm HCCs and its influence on liver function. Materials and methods All 5-cm HCCs treated by MWA and cTACE performed in a single-session in our Interventional Radiology unit between January 2020 and December 2022 were retrospectively recorded and analyzed. Patients with poor or missing pre- and post-treatment imaging were excluded. Technical success, clinical success, and complications rate were examined as primary endpoints. Pre- and post-treatment liver function laboratory parameters were also evaluated. Results A total of 15 lesions (mean lesion diameter, 5.0 ± 1.4 cm) in 15 patients (11 men; mean age, 67.1 ± 8.9 years) were retrospectively evaluated. Technical and clinical success were 100% and 73%, respectively. Four (27%) cases of partial response and no cases of progressive or stable disease were recorded. AST and ALT values have found to be significantly higher in post-treatment laboratory tests. No other significant differences between pre- and post-treatment laboratory values were registered. AST and ALT pre- and post-treatment higher differences (ΔAST and ΔALT) were significantly associated with a lower clinical success rate. Conclusion MWA and cTACE single-session approach is safe and effective for 5-cm HCCs, without significant liver function impairment. A post-treatment increase in AST and ALT values may be a predictor for clinical failure.

show abstract

Transarterial Chemoembolization Combined With Radiofrequency Ablation Versus Hepatectomy for Hepatocellular Carcinoma: A Meta-Analysis

Cited by 4 publications

References 37 publications

Radiofrequency ablation combined with transcatheter arterial chemoembolization for recurrent liver cancer

Radiofrequency ablation combined with transcatheter arterial chemoembolization for recurrent liver cancer

Chemoembolization Plus Ablation: Current Status

Microwave ablation followed by cTACE in 5-cm HCC lesions: does a single-session approach affect liver function?

Contact Info

Product

Resources

About